Traders sold shares of Becton, Dickinson and Company (NYSE:BDX) on strength during trading on Tuesday. $32.54 million flowed into the stock on the tick-up and $57.51 million flowed out of the stock on the tick-down, for a money net flow of $24.97 million out of the stock. Of all stocks tracked, Becton, Dickinson and had the 0th highest net out-flow for the day. Becton, Dickinson and traded up $0.92 for the day and closed at $200.07

Several brokerages have recently commented on BDX. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 target price on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $195.79.

The stock has a market capitalization of $45.43 billion, a PE ratio of 57.82 and a beta of 1.06. The stock’s 50 day moving average price is $200.18 and its 200-day moving average price is $190.58.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the business posted $2.35 EPS. The company’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold 48,605 shares of company stock valued at $9,718,986 over the last 90 days. Company insiders own 1.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Boston Financial Mangement LLC increased its stake in Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock valued at $10,218,000 after acquiring an additional 5,152 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Becton, Dickinson and by 5.8% in the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock valued at $6,438,000 after buying an additional 1,819 shares in the last quarter. Wells Fargo & Company MN boosted its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares in the last quarter. AMG National Trust Bank boosted its position in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after buying an additional 401 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in Becton, Dickinson and by 1.4% in the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock valued at $190,827,000 after buying an additional 13,263 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/07/traders-sell-shares-of-becton-dickinson-and-company-bdx-on-strength-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.